I guess egregious is in the eye of the beholder. LP is actually enabling a cost effective total execution of getting from zero to approvals. Here’s the logic:
1. As Senti noted, LP’s compensation covers several titles instead of paying additional individuals
2. The much greater efficiencies come from pulling off massively parallel accomplishments such as :
A. One phase 3 including and applying to US, UK, Ca, EU
B. One SAP and one base application
C. Firm ground work for tissue agnostic applicability
D. Acquired basis of automated closed system production-> scaling multiplier
I’ll stop at this point, which I think establishes the value of highly intelligent planning and the wherewithal to innovate the production and even the approval processes along with the regulatory agencies. I believe LP has been key to all this trailblazing new advances.